ID   CSF1R_HUMAN             Reviewed;         972 AA.
AC   P07333; B5A955; D3DQG2; Q6LDW5; Q6LDY4; Q86VW7;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   12-OCT-2022, entry version 236.
DE   RecName: Full=Macrophage colony-stimulating factor 1 receptor;
DE   AltName: Full=CSF-1 receptor;
DE            Short=CSF-1-R;
DE            Short=CSF-1R;
DE            Short=M-CSF-R;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-Fms;
DE   AltName: CD_antigen=CD115;
DE   Flags: Precursor;
GN   Name=CSF1R; Synonyms=FMS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2524025;
RA   Hampe A., Shamoon B.M., Gobet M., Sherr C.J., Galibert F.;
RT   "Nucleotide sequence and structural organization of the human FMS proto-
RT   oncogene.";
RL   Oncogene Res. 4:9-17(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2421165; DOI=10.1038/320277a0;
RA   Coussens L., van Beveren C., Smith D., Chen E., Mitchell R.L., Isacke C.M.,
RA   Verma I.M., Ullrich A.;
RT   "Structural alteration of viral homologue of receptor proto-oncogene fms at
RT   carboxyl terminus.";
RL   Nature 320:277-280(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=9027509; DOI=10.1006/geno.1996.4482;
RA   Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V., Hu W.X.,
RA   Galibert F.;
RT   "Sequence analysis of two genomic regions containing the KIT and the FMS
RT   receptor tyrosine kinase genes.";
RL   Genomics 39:216-226(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   PubMed=2524648; DOI=10.1128/mcb.9.3.1336-1341.1989;
RA   Visvader J., Verma I.M.;
RT   "Differential transcription of exon 1 of the human c-fms gene in placental
RT   trophoblasts and monocytes.";
RL   Mol. Cell. Biol. 9:1336-1341(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   PubMed=3525854; DOI=10.1128/jvi.59.2.224-233.1986;
RA   Wheeler E.F., Roussel M.F., Hampe A., Walker M.H., Fried V.A., Look A.T.,
RA   Rettenmier C.W., Sherr C.J.;
RT   "The amino-terminal domain of the v-fms oncogene product includes a
RT   functional signal peptide that directs synthesis of a transforming
RT   glycoprotein in the absence of feline leukemia virus gag sequences.";
RL   J. Virol. 59:224-233(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RC   TISSUE=Placenta;
RA   Flick M.B., Sapi E., Kacinski B.M.;
RT   "Expression of a novel exon in the 5' UTR of human c-fms transcripts.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 244-295.
RX   PubMed=4028159; DOI=10.1016/0092-8674(85)90099-6;
RA   Nienhuis A.W., Bunn H.F., Turner P.H., Gopal T.V., Nash W.G., O'Brien S.J.,
RA   Sherr C.J.;
RT   "Expression of the human c-fms proto-oncogene in hematopoietic cells and
RT   its deletion in the 5q- syndrome.";
RL   Cell 42:421-428(1985).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 874-972 (ISOFORM 1).
RX   PubMed=3532121; DOI=10.1073/pnas.83.20.7800;
RA   Browning P.J., Bunn H.F., Cline A., Shuman M., Nienhuis A.W.;
RT   "'Replacement' of COOH-terminal truncation of v-fms with c-fms sequences
RT   markedly reduces transformation potential.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7800-7804(1986).
RN   [13]
RP   FUNCTION IN CELL PROLIFERATION.
RX   PubMed=7683918;
RA   Bourette R.P., Mouchiroud G., Ouazana R., Morle F., Godet J.,
RA   Blanchet J.P.;
RT   "Expression of human colony-stimulating factor-1 (CSF-1) receptor in murine
RT   pluripotent hematopoietic NFS-60 cells induces long-term proliferation in
RT   response to CSF-1 without loss of erythroid differentiation potential.";
RL   Blood 81:2511-2520(1993).
RN   [14]
RP   INTERACTION WITH SRC; FYN AND YES1, AND MUTAGENESIS OF TYR-809.
RX   PubMed=7681396; DOI=10.1002/j.1460-2075.1993.tb05735.x;
RA   Courtneidge S.A., Dhand R., Pilat D., Twamley G.M., Waterfield M.D.,
RA   Roussel M.F.;
RT   "Activation of Src family kinases by colony stimulating factor-1, and their
RT   association with its receptor.";
RL   EMBO J. 12:943-950(1993).
RN   [15]
RP   INDUCTION BY GLUCOCORTICOIDS.
RX   PubMed=7845678;
RA   Sapi E., Flick M.B., Gilmore-Hebert M., Rodov S., Kacinski B.M.;
RT   "Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human
RT   breast carcinoma cells by glucocorticoids.";
RL   Oncogene 10:529-542(1995).
RN   [16]
RP   MUTAGENESIS OF TYR-708 AND ASP-802.
RX   PubMed=10340379; DOI=10.1038/sj.onc.1202646;
RA   Morley G.M., Uden M., Gullick W.J., Dibb N.J.;
RT   "Cell specific transformation by c-fms activating loop mutations is
RT   attributable to constitutive receptor degradation.";
RL   Oncogene 18:3076-3084(1999).
RN   [17]
RP   FUNCTION IN CELLULAR SIGNALING; PHOSPHORYLATION OF INPP5D AND ACTIVATION OF
RP   AKT1.
RX   PubMed=12882960; DOI=10.1074/jbc.m305021200;
RA   Baran C.P., Tridandapani S., Helgason C.D., Humphries R.K., Krystal G.,
RA   Marsh C.B.;
RT   "The inositol 5'-phosphatase SHIP-1 and the Src kinase Lyn negatively
RT   regulate macrophage colony-stimulating factor-induced Akt activity.";
RL   J. Biol. Chem. 278:38628-38636(2003).
RN   [18]
RP   FUNCTION IN REGULATION OF CELL PROLIFERATION; CELL ADHESION; CELL SHAPE AND
RP   INTEGRITY OF CELL JUNCTIONS, MUTAGENESIS OF LEU-301 AND TYR-969, AND ROLE
RP   IN DISEASE.
RX   PubMed=15117969; DOI=10.1083/jcb.200309102;
RA   Wrobel C.N., Debnath J., Lin E., Beausoleil S., Roussel M.F., Brugge J.S.;
RT   "Autocrine CSF-1R activation promotes Src-dependent disruption of mammary
RT   epithelial architecture.";
RL   J. Cell Biol. 165:263-273(2004).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-302 AND ASN-353.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [20]
RP   FUNCTION AS CSF1 RECEPTOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, ROLE IN
RP   DISEASE, AND ACTIVITY REGULATION.
RX   PubMed=16648572; DOI=10.1158/1535-7163.mct-05-0359;
RA   Guo J., Marcotte P.A., McCall J.O., Dai Y., Pease L.J., Michaelides M.R.,
RA   Davidsen S.K., Glaser K.B.;
RT   "Inhibition of phosphorylation of the colony-stimulating factor-1 receptor
RT   (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine
RT   kinase inhibitors.";
RL   Mol. Cancer Ther. 5:1007-1013(2006).
RN   [21]
RP   FUNCTION IN CELL PROLIFERATION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION,
RP   ROLE IN DISEASE, AND ACTIVITY REGULATION.
RX   PubMed=17121910; DOI=10.1158/1535-7163.mct-05-0313;
RA   Ohno H., Kubo K., Murooka H., Kobayashi Y., Nishitoba T., Shibuya M.,
RA   Yoneda T., Isoe T.;
RT   "A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast
RT   differentiation and osteolytic bone destruction in a bone metastasis
RT   model.";
RL   Mol. Cancer Ther. 5:2634-2643(2006).
RN   [22]
RP   FUNCTION IN REGULATION OF CELL PROLIFERATION AND CELL SHAPE, CATALYTIC
RP   ACTIVITY, UBIQUITINATION, ACTIVITY REGULATION, AND MUTAGENESIS OF ASP-802.
RX   PubMed=16170366; DOI=10.1038/sj.onc.1209007;
RA   Taylor J.R., Brownlow N., Domin J., Dibb N.J.;
RT   "FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor
RT   imatinib and mutation of Asp-802 to Val confers resistance.";
RL   Oncogene 25:147-151(2006).
RN   [23]
RP   FUNCTION AS IL34 RECEPTOR.
RX   PubMed=18467591; DOI=10.1126/science.1154370;
RA   Lin H., Lee E., Hestir K., Leo C., Huang M., Bosch E., Halenbeck R., Wu G.,
RA   Zhou A., Behrens D., Hollenbaugh D., Linnemann T., Qin M., Wong J., Chu K.,
RA   Doberstein S.K., Williams L.T.;
RT   "Discovery of a cytokine and its receptor by functional screening of the
RT   extracellular proteome.";
RL   Science 320:807-811(2008).
RN   [24]
RP   ROLE IN DISEASE, AND ACTIVITY REGULATION.
RX   PubMed=18814279; DOI=10.1002/ijc.23903;
RA   Hiraga T., Nakamura H.;
RT   "Imatinib mesylate suppresses bone metastases of breast cancer by
RT   inhibiting osteoclasts through the blockade of c-Fms signals.";
RL   Int. J. Cancer 124:215-222(2009).
RN   [25]
RP   ROLE IN DISEASE.
RX   PubMed=19934330; DOI=10.1158/0008-5472.can-09-1868;
RA   Patsialou A., Wyckoff J., Wang Y., Goswami S., Stanley E.R.,
RA   Condeelis J.S.;
RT   "Invasion of human breast cancer cells in vivo requires both paracrine and
RT   autocrine loops involving the colony-stimulating factor-1 receptor.";
RL   Cancer Res. 69:9498-9506(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-699 AND SER-713, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION.
RX   PubMed=20156689; DOI=10.1016/j.bmc.2010.01.056;
RA   Mashkani B., Griffith R., Ashman L.K.;
RT   "Colony stimulating factor-1 receptor as a target for small molecule
RT   inhibitors.";
RL   Bioorg. Med. Chem. 18:1789-1797(2010).
RN   [28]
RP   FUNCTION AS RECEPTOR FOR IL34 AND CSF1, PHOSPHORYLATION AT TYR-546;
RP   TYR-699; TYR-708; TYR-723 AND TYR-809, AUTOPHOSPHORYLATION, ACTIVITY
RP   REGULATION, AND INTERACTION WITH IL34 AND CSF1.
RX   PubMed=20489731; DOI=10.1038/cdd.2010.60;
RA   Chihara T., Suzu S., Hassan R., Chutiwitoonchai N., Hiyoshi M.,
RA   Motoyoshi K., Kimura F., Okada S.;
RT   "IL-34 and M-CSF share the receptor Fms but are not identical in biological
RT   activity and signal activation.";
RL   Cell Death Differ. 17:1917-1927(2010).
RN   [29]
RP   FUNCTION IN RELEASE OF PRO-INFLAMMATORY CHEMOKINES.
RX   PubMed=20829061; DOI=10.1016/j.cyto.2010.08.005;
RA   Eda H., Zhang J., Keith R.H., Michener M., Beidler D.R., Monahan J.B.;
RT   "Macrophage-colony stimulating factor and interleukin-34 induce chemokines
RT   in human whole blood.";
RL   Cytokine 52:215-220(2010).
RN   [30]
RP   FUNCTION AS IL34 AND CSF1 RECEPTOR; ACTIVATION OF MAPK1/ERK2; MAPK3/ERK1;
RP   PHOSPHORYLATION AT TYR-723, AND AUTOPHOSPHORYLATION.
RX   PubMed=20504948; DOI=10.1189/jlb.1209822;
RA   Wei S., Nandi S., Chitu V., Yeung Y.G., Yu W., Huang M., Williams L.T.,
RA   Lin H., Stanley E.R.;
RT   "Functional overlap but differential expression of CSF-1 and IL-34 in their
RT   CSF-1 receptor-mediated regulation of myeloid cells.";
RL   J. Leukoc. Biol. 88:495-505(2010).
RN   [31]
RP   REVIEW ON FUNCTION; SIGNALING PATHWAYS AND PHOSPHORYLATION.
RX   PubMed=15519852; DOI=10.1016/j.tcb.2004.09.016;
RA   Pixley F.J., Stanley E.R.;
RT   "CSF-1 regulation of the wandering macrophage: complexity in action.";
RL   Trends Cell Biol. 14:628-638(2004).
RN   [32]
RP   REVIEW ON FUNCTION IN IMMUNITY AND INFLAMMATION, AND ROLE IN DISEASE.
RX   PubMed=16337366; DOI=10.1016/j.coi.2005.11.006;
RA   Chitu V., Stanley E.R.;
RT   "Colony-stimulating factor-1 in immunity and inflammation.";
RL   Curr. Opin. Immunol. 18:39-48(2006).
RN   [33]
RP   REVIEW ON FUNCTION; SIGNALING PATHWAYS AND PHOSPHORYLATION.
RX   PubMed=18687298; DOI=10.1016/j.intimp.2008.04.016;
RA   Douglass T.G., Driggers L., Zhang J.G., Hoa N., Delgado C., Williams C.C.,
RA   Dan Q., Sanchez R., Jeffes E.W., Wepsic H.T., Myers M.P., Koths K.,
RA   Jadus M.R.;
RT   "Macrophage colony stimulating factor: not just for macrophages anymore! A
RT   gateway into complex biologies.";
RL   Int. Immunopharmacol. 8:1354-1376(2008).
RN   [34]
RP   REVIEW.
RX   PubMed=19132917; DOI=10.1146/annurev.immunol.021908.132557;
RA   Auffray C., Sieweke M.H., Geissmann F.;
RT   "Blood monocytes: development, heterogeneity, and relationship with
RT   dendritic cells.";
RL   Annu. Rev. Immunol. 27:669-692(2009).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 538-922 IN COMPLEXES WITH
RP   ARYLAMIDE AND QUINOLONE INHIBITORS, AND DOMAIN.
RX   PubMed=17132624; DOI=10.1074/jbc.m608183200;
RA   Schubert C., Schalk-Hihi C., Struble G.T., Ma H.C., Petrounia I.P.,
RA   Brandt B., Deckman I.C., Patch R.J., Player M.R., Spurlino J.C.,
RA   Springer B.A.;
RT   "Crystal structure of the tyrosine kinase domain of colony-stimulating
RT   factor-1 receptor (cFMS) in complex with two inhibitors.";
RL   J. Biol. Chem. 282:4094-4101(2007).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 543-918 IN AUTOINHIBITED
RP   CONFORMATION, AND DOMAIN.
RX   PubMed=17292918; DOI=10.1016/j.jmb.2007.01.036;
RA   Walter M., Lucet I.S., Patel O., Broughton S.E., Bamert R., Williams N.K.,
RA   Fantino E., Wilks A.F., Rossjohn J.;
RT   "The 2.7 A crystal structure of the autoinhibited human c-Fms kinase
RT   domain.";
RL   J. Mol. Biol. 367:839-847(2007).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.02 ANGSTROMS) OF 538-922 IN COMPLEX WITH
RP   PYRIMIDINOPYRIDONE INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=18342505; DOI=10.1016/j.bmcl.2008.02.070;
RA   Huang H., Hutta D.A., Hu H., DesJarlais R.L., Schubert C., Petrounia I.P.,
RA   Chaikin M.A., Manthey C.L., Player M.R.;
RT   "Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-
RT   inflammatory FMS inhibitors.";
RL   Bioorg. Med. Chem. Lett. 18:2355-2361(2008).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 538-922 IN COMPLEX WITH
RP   INHIBITOR, CATALYTIC ACTIVITY, AND FUNCTION IN INFLAMMATION AND DISEASE.
RX   PubMed=19193011; DOI=10.1021/jm801406h;
RA   Huang H., Hutta D.A., Rinker J.M., Hu H., Parsons W.H., Schubert C.,
RA   DesJarlais R.L., Crysler C.S., Chaikin M.A., Donatelli R.R., Chen Y.,
RA   Cheng D., Zhou Z., Yurkow E., Manthey C.L., Player M.R.;
RT   "Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory
RT   macrophage colony-stimulating factor-1 receptor inhibitors.";
RL   J. Med. Chem. 52:1081-1099(2009).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 538-922 IN COMPLEXES WITH
RP   INHIBITORS, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=20137931; DOI=10.1016/j.bmcl.2010.01.078;
RA   Meyers M.J., Pelc M., Kamtekar S., Day J., Poda G.I., Hall M.K.,
RA   Michener M.L., Reitz B.A., Mathis K.J., Pierce B.S., Parikh M.D.,
RA   Mischke D.A., Long S.A., Parlow J.J., Anderson D.R., Thorarensen A.;
RT   "Structure-based drug design enables conversion of a DFG-in binding CSF-1R
RT   kinase inhibitor to a DFG-out binding mode.";
RL   Bioorg. Med. Chem. Lett. 20:1543-1547(2010).
RN   [41]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-32; ARG-362; SER-413; VAL-536; HIS-693;
RP   ASP-920 AND GLN-921.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [42]
RP   VARIANTS HDLS1 774-CYS--ASN-814 DEL; 585-GLY--LYS-619 DELINS ALA; GLU-589;
RP   LYS-633; THR-766; PRO-770; ASN-775; THR-794; TYR-837; SER-849; PHE-849 DEL;
RP   PRO-868; THR-875 AND THR-878, VARIANTS HIS-710; ARG-747 AND ASP-920, AND
RP   CHARACTERIZATION OF VARIANTS HDLS1 LYS-633; THR-766 AND THR-875.
RX   PubMed=22197934; DOI=10.1038/ng.1027;
RA   Rademakers R., Baker M., Nicholson A.M., Rutherford N.J., Finch N.,
RA   Soto-Ortolaza A., Lash J., Wider C., Wojtas A., DeJesus-Hernandez M.,
RA   Adamson J., Kouri N., Sundal C., Shuster E.A., Aasly J., MacKenzie J.,
RA   Roeber S., Kretzschmar H.A., Boeve B.F., Knopman D.S., Petersen R.C.,
RA   Cairns N.J., Ghetti B., Spina S., Garbern J., Tselis A.C., Uitti R.,
RA   Das P., Van Gerpen J.A., Meschia J.F., Levy S., Broderick D.F.,
RA   Graff-Radford N., Ross O.A., Miller B.B., Swerdlow R.H., Dickson D.W.,
RA   Wszolek Z.K.;
RT   "Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause
RT   hereditary diffuse leukoencephalopathy with spheroids.";
RL   Nat. Genet. 44:200-205(2012).
RN   [43]
RP   VARIANTS HDLS1 THR-766 AND HIS-782, CHARACTERIZATION OF VARIANTS HDLS1
RP   HIS-782 AND THR-875, AND AUTOPHOSPHORYLATION.
RX   PubMed=23408870; DOI=10.1212/wnl.0b013e31828726a7;
RA   Nicholson A.M., Baker M.C., Finch N.A., Rutherford N.J., Wider C.,
RA   Graff-Radford N.R., Nelson P.T., Clark H.B., Wszolek Z.K., Dickson D.W.,
RA   Knopman D.S., Rademakers R.;
RT   "CSF1R mutations link POLD and HDLS as a single disease entity.";
RL   Neurology 80:1033-1040(2013).
RN   [44]
RP   VARIANTS HDLS1 ARG-653; PHE-843 AND THR-906.
RX   PubMed=24532199; DOI=10.1007/s00415-014-7257-3;
RA   Battisti C., Di Donato I., Bianchi S., Monti L., Formichi P., Rufa A.,
RA   Taglia I., Cerase A., Dotti M.T., Federico A.;
RT   "Hereditary diffuse leukoencephalopathy with axonal spheroids: three
RT   patients with stroke-like presentation carrying new mutations in the CSF1R
RT   gene.";
RL   J. Neurol. 261:768-772(2014).
RN   [45]
RP   VARIANTS HDLS1 ASP-765; GLU-781; THR-794 AND SER-824, CHARACTERIZATION OF
RP   VARIANTS HDLS1 ASP-765; GLU-781; THR-794 AND SER-824, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=24336230; DOI=10.1212/wnl.0000000000000046;
RA   Konno T., Tada M., Tada M., Koyama A., Nozaki H., Harigaya Y.,
RA   Nishimiya J., Matsunaga A., Yoshikura N., Ishihara K., Arakawa M.,
RA   Isami A., Okazaki K., Yokoo H., Itoh K., Yoneda M., Kawamura M.,
RA   Inuzuka T., Takahashi H., Nishizawa M., Onodera O., Kakita A., Ikeuchi T.;
RT   "Haploinsufficiency of CSF-1R and clinicopathologic characterization in
RT   patients with HDLS.";
RL   Neurology 82:139-148(2014).
RN   [46]
RP   INVOLVEMENT IN BANDDOS, VARIANTS BANDDOS LEU-132; GLN-481--972-CYS DEL AND
RP   LYS-627 DEL, CHARACTERIZATION OF VARIANTS BANDDOS LEU-132 AND LYS-627 DEL,
RP   AND FUNCTION.
RX   PubMed=30982609; DOI=10.1016/j.ajhg.2019.03.004;
RA   Guo L., Bertola D.R., Takanohashi A., Saito A., Segawa Y., Yokota T.,
RA   Ishibashi S., Nishida Y., Yamamoto G.L., Franco J.F.D.S., Honjo R.S.,
RA   Kim C.A., Musso C.M., Timmons M., Pizzino A., Taft R.J., Lajoie B.,
RA   Knight M.A., Fischbeck K.H., Singleton A.B., Ferreira C.R., Wang Z.,
RA   Yan L., Garbern J.Y., Simsek-Kiper P.O., Ohashi H., Robey P.G., Boyde A.,
RA   Matsumoto N., Miyake N., Spranger J., Schiffmann R., Vanderver A.,
RA   Nishimura G., Passos-Bueno M.R.D.S., Simons C., Ishikawa K., Ikegawa S.;
RT   "Bi-allelic CSF1R Mutations Cause Skeletal Dysplasia of Dysosteosclerosis-
RT   Pyle Disease Spectrum and Degenerative Encephalopathy with Brain
RT   Malformation.";
RL   Am. J. Hum. Genet. 104:925-935(2019).
RN   [47]
RP   VARIANT BANDDOS GLN-643, AND FUNCTION.
RX   PubMed=30982608; DOI=10.1016/j.ajhg.2019.03.010;
RA   Oosterhof N., Chang I.J., Karimiani E.G., Kuil L.E., Jensen D.M., Daza R.,
RA   Young E., Astle L., van der Linde H.C., Shivaram G.M., Demmers J.,
RA   Latimer C.S., Keene C.D., Loter E., Maroofian R., van Ham T.J.,
RA   Hevner R.F., Bennett J.T.;
RT   "Homozygous Mutations in CSF1R Cause a Pediatric-Onset Leukoencephalopathy
RT   and Can Result in Congenital Absence of Microglia.";
RL   Am. J. Hum. Genet. 104:936-947(2019).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor
CC       for CSF1 and IL34 and plays an essential role in the regulation of
CC       survival, proliferation and differentiation of hematopoietic precursor
CC       cells, especially mononuclear phagocytes, such as macrophages and
CC       monocytes. Promotes the release of pro-inflammatory chemokines in
CC       response to IL34 and CSF1, and thereby plays an important role in
CC       innate immunity and in inflammatory processes. Plays an important role
CC       in the regulation of osteoclast proliferation and differentiation, the
CC       regulation of bone resorption, and is required for normal bone and
CC       tooth development. Required for normal male and female fertility, and
CC       for normal development of milk ducts and acinar structures in the
CC       mammary gland during pregnancy. Promotes reorganization of the actin
CC       cytoskeleton, regulates formation of membrane ruffles, cell adhesion
CC       and cell migration, and promotes cancer cell invasion. Activates
CC       several signaling pathways in response to ligand binding, including the
CC       ERK1/2 and the JNK pathway (PubMed:20504948, PubMed:30982609).
CC       Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL. Activation of PLCG2
CC       leads to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate, that then lead to the
CC       activation of protein kinase C family members, especially PRKCD.
CC       Phosphorylation of PIK3R1, the regulatory subunit of
CC       phosphatidylinositol 3-kinase, leads to activation of the AKT1
CC       signaling pathway. Activated CSF1R also mediates activation of the MAP
CC       kinases MAPK1/ERK2 and/or MAPK3/ERK1, and of the SRC family kinases
CC       SRC, FYN and YES1. Activated CSF1R transmits signals both via proteins
CC       that directly interact with phosphorylated tyrosine residues in its
CC       intracellular domain, or via adapter proteins, such as GRB2. Promotes
CC       activation of STAT family members STAT3, STAT5A and/or STAT5B. Promotes
CC       tyrosine phosphorylation of SHC1 and INPP5D/SHIP-1. Receptor signaling
CC       is down-regulated by protein phosphatases, such as INPP5D/SHIP-1, that
CC       dephosphorylate the receptor and its downstream effectors, and by rapid
CC       internalization of the activated receptor. In the central nervous
CC       system, may play a role in the development of microglia macrophages
CC       (PubMed:30982608). {ECO:0000269|PubMed:12882960,
CC       ECO:0000269|PubMed:15117969, ECO:0000269|PubMed:16170366,
CC       ECO:0000269|PubMed:16337366, ECO:0000269|PubMed:16648572,
CC       ECO:0000269|PubMed:17121910, ECO:0000269|PubMed:18467591,
CC       ECO:0000269|PubMed:18814279, ECO:0000269|PubMed:19193011,
CC       ECO:0000269|PubMed:19934330, ECO:0000269|PubMed:20489731,
CC       ECO:0000269|PubMed:20504948, ECO:0000269|PubMed:20829061,
CC       ECO:0000269|PubMed:30982608, ECO:0000269|PubMed:30982609,
CC       ECO:0000269|PubMed:7683918}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:16170366, ECO:0000269|PubMed:16648572,
CC         ECO:0000269|PubMed:17121910, ECO:0000269|PubMed:18342505,
CC         ECO:0000269|PubMed:19193011, ECO:0000269|PubMed:20137931};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. CSF1 or IL34 binding leads to dimerization and
CC       activation by autophosphorylation on tyrosine residues. Inhibited by
CC       imatinib/STI-571 (Gleevec), dasatinib, sunitinib/SU11248,
CC       lestaurtinib/CEP-701, midostaurin/PKC-412, Ki20227, linifanib/ABT-869,
CC       Axitinib/AG013736, sorafenib/BAY 43-9006 and GW2580.
CC       {ECO:0000269|PubMed:16170366, ECO:0000269|PubMed:16648572,
CC       ECO:0000269|PubMed:17121910, ECO:0000269|PubMed:18814279,
CC       ECO:0000269|PubMed:20137931, ECO:0000269|PubMed:20156689,
CC       ECO:0000269|PubMed:20489731}.
CC   -!- SUBUNIT: Interacts with INPPL1/SHIP2 and THOC5 (By similarity).
CC       Monomer. Homodimer. Interacts with CSF1 and IL34. Interaction with
CC       dimeric CSF1 or IL34 leads to receptor homodimerization. Interacts
CC       (tyrosine phosphorylated) with PLCG2 (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with PIK3R1 (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with FYN, YES1 and SRC (via SH2 domain).
CC       Interacts (tyrosine phosphorylated) with CBL, GRB2 and SLA2.
CC       {ECO:0000250, ECO:0000269|PubMed:18342505, ECO:0000269|PubMed:19193011,
CC       ECO:0000269|PubMed:20489731, ECO:0000269|PubMed:7681396}.
CC   -!- INTERACTION:
CC       P07333; P09603: CSF1; NbExp=13; IntAct=EBI-2835440, EBI-2872294;
CC       P07333; Q15375: EPHA7; NbExp=2; IntAct=EBI-2835440, EBI-1383428;
CC       P07333; P29323: EPHB2; NbExp=2; IntAct=EBI-2835440, EBI-1059294;
CC       P07333; Q6ZMJ4-1: IL34; NbExp=9; IntAct=EBI-2835440, EBI-15978980;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P07333-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P07333-2; Sequence=VSP_047757, VSP_047758;
CC   -!- TISSUE SPECIFICITY: Expressed in bone marrow and in differentiated
CC       blood mononuclear cells.
CC   -!- INDUCTION: Up-regulated by glucocorticoids.
CC       {ECO:0000269|PubMed:7845678}.
CC   -!- DOMAIN: The juxtamembrane domain functions as autoinhibitory region.
CC       Phosphorylation of tyrosine residues in this region leads to a
CC       conformation change and activation of the kinase.
CC   -!- DOMAIN: The activation loop plays an important role in the regulation
CC       of kinase activity. Phosphorylation of tyrosine residues in this region
CC       leads to a conformation change and activation of the kinase.
CC   -!- PTM: Autophosphorylated in response to CSF1 or IL34 binding
CC       (PubMed:24336230, PubMed:20489731, PubMed:23408870). Phosphorylation at
CC       Tyr-561 is important for normal down-regulation of signaling by
CC       ubiquitination, internalization and degradation. Phosphorylation at
CC       Tyr-561 and Tyr-809 is important for interaction with SRC family
CC       members, including FYN, YES1 and SRC, and for subsequent activation of
CC       these protein kinases. Phosphorylation at Tyr-699 and Tyr-923 is
CC       important for interaction with GRB2. Phosphorylation at Tyr-723 is
CC       important for interaction with PIK3R1. Phosphorylation at Tyr-708 is
CC       important for normal receptor degradation. Phosphorylation at Tyr-723
CC       and Tyr-809 is important for interaction with PLCG2. Phosphorylation at
CC       Tyr-969 is important for interaction with CBL. Dephosphorylation by
CC       PTPN2 negatively regulates downstream signaling and macrophage
CC       differentiation. {ECO:0000269|PubMed:16170366,
CC       ECO:0000269|PubMed:20489731, ECO:0000269|PubMed:23408870,
CC       ECO:0000269|PubMed:24336230}.
CC   -!- PTM: Ubiquitinated. Becomes rapidly polyubiquitinated after
CC       autophosphorylation, leading to its degradation.
CC       {ECO:0000269|PubMed:16170366}.
CC   -!- DISEASE: Note=Aberrant expression of CSF1 or CSF1R can promote cancer
CC       cell proliferation, invasion and formation of metastases.
CC       Overexpression of CSF1 or CSF1R is observed in a significant percentage
CC       of breast, ovarian, prostate, and endometrial cancers.
CC   -!- DISEASE: Note=Aberrant expression of CSF1 or CSF1R may play a role in
CC       inflammatory diseases, such as rheumatoid arthritis,
CC       glomerulonephritis, atherosclerosis, and allograft rejection.
CC   -!- DISEASE: Leukoencephalopathy, hereditary diffuse, with spheroids 1
CC       (HDLS1) [MIM:221820]: An autosomal dominant adult-onset rapidly
CC       progressive neurodegenerative disorder characterized by variable
CC       behavioral, cognitive, and motor changes. Patients often die of
CC       dementia within 6 years of onset. Brain imaging shows patchy
CC       abnormalities in the cerebral white matter, predominantly affecting the
CC       frontal and parietal lobes. {ECO:0000269|PubMed:22197934,
CC       ECO:0000269|PubMed:23408870, ECO:0000269|PubMed:24336230,
CC       ECO:0000269|PubMed:24532199}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Brain abnormalities, neurodegeneration, and dysosteosclerosis
CC       (BANDDOS) [MIM:618476]: An autosomal recessive disease with variable
CC       manifestations. Main features are brain malformations with calcifying
CC       leukoencephalopathy, progressive neurodegeneration, and bone sclerotic
CC       features. The age at onset ranges from infancy to early adulthood.
CC       Neurologic features include loss of previous motor and language skills,
CC       cognitive impairment, spasticity, and focal seizures. Brain imaging
CC       shows periventricular white matter abnormalities and calcifications,
CC       large cisterna magna or Dandy-Walker malformation, and sometimes
CC       agenesis of the corpus callosum. {ECO:0000269|PubMed:30982608,
CC       ECO:0000269|PubMed:30982609}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CSF1RID40161ch5q32.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X03663; CAA27300.1; -; mRNA.
DR   EMBL; U63963; AAB51696.1; -; Genomic_DNA.
DR   EMBL; M25786; AAA58421.1; -; mRNA.
DR   EMBL; EU826593; ACF47629.1; -; mRNA.
DR   EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471062; EAW61749.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61750.1; -; Genomic_DNA.
DR   EMBL; BC047521; AAH47521.1; -; mRNA.
DR   EMBL; M14002; AAA35849.1; -; Genomic_DNA.
DR   EMBL; U78096; AAB51235.1; -; Genomic_DNA.
DR   EMBL; M11067; AAA35848.1; -; Genomic_DNA.
DR   EMBL; M14193; AAA35834.1; -; mRNA.
DR   CCDS; CCDS4302.1; -. [P07333-1]
DR   PIR; S08123; TVHUMD.
DR   RefSeq; NP_001275634.1; NM_001288705.2. [P07333-1]
DR   RefSeq; NP_005202.2; NM_005211.3. [P07333-1]
DR   PDB; 2I0V; X-ray; 2.80 A; A=538-678, A=753-922.
DR   PDB; 2I0Y; X-ray; 1.90 A; A=538-678, A=753-922.
DR   PDB; 2I1M; X-ray; 1.80 A; A=538-678, A=753-922.
DR   PDB; 2OGV; X-ray; 2.70 A; A=543-918.
DR   PDB; 3BEA; X-ray; 2.02 A; A=538-678, A=753-922.
DR   PDB; 3DPK; X-ray; 1.95 A; A=538-678, A=771-922.
DR   PDB; 3KRJ; X-ray; 2.10 A; A=538-678, A=753-922.
DR   PDB; 3KRL; X-ray; 2.40 A; A=538-678, A=753-922.
DR   PDB; 3LCD; X-ray; 2.50 A; A=538-919.
DR   PDB; 3LCO; X-ray; 3.40 A; A=550-919.
DR   PDB; 4DKD; X-ray; 3.00 A; C=20-299.
DR   PDB; 4HW7; X-ray; 2.90 A; A=542-919.
DR   PDB; 4LIQ; X-ray; 2.60 A; E=2-512.
DR   PDB; 4R7H; X-ray; 2.80 A; A=542-919.
DR   PDB; 4R7I; X-ray; 2.75 A; A=542-919.
DR   PDB; 4WRL; X-ray; 2.80 A; A/C=20-296.
DR   PDB; 4WRM; X-ray; 6.85 A; A=20-504.
DR   PDB; 6IG8; X-ray; 1.80 A; A=550-919.
DR   PDB; 6N33; X-ray; 2.25 A; A=542-919.
DR   PDB; 6T2W; X-ray; 1.70 A; A=542-919.
DR   PDB; 6WXJ; X-ray; 2.62 A; A=538-678, A=753-922.
DR   PDB; 7MFC; X-ray; 2.80 A; A=542-919.
DR   PDBsum; 2I0V; -.
DR   PDBsum; 2I0Y; -.
DR   PDBsum; 2I1M; -.
DR   PDBsum; 2OGV; -.
DR   PDBsum; 3BEA; -.
DR   PDBsum; 3DPK; -.
DR   PDBsum; 3KRJ; -.
DR   PDBsum; 3KRL; -.
DR   PDBsum; 3LCD; -.
DR   PDBsum; 3LCO; -.
DR   PDBsum; 4DKD; -.
DR   PDBsum; 4HW7; -.
DR   PDBsum; 4LIQ; -.
DR   PDBsum; 4R7H; -.
DR   PDBsum; 4R7I; -.
DR   PDBsum; 4WRL; -.
DR   PDBsum; 4WRM; -.
DR   PDBsum; 6IG8; -.
DR   PDBsum; 6N33; -.
DR   PDBsum; 6T2W; -.
DR   PDBsum; 6WXJ; -.
DR   PDBsum; 7MFC; -.
DR   AlphaFoldDB; P07333; -.
DR   SMR; P07333; -.
DR   BioGRID; 107823; 31.
DR   DIP; DIP-59421N; -.
DR   IntAct; P07333; 53.
DR   MINT; P07333; -.
DR   STRING; 9606.ENSP00000286301; -.
DR   BindingDB; P07333; -.
DR   ChEMBL; CHEMBL1844; -.
DR   DrugBank; DB07167; 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE.
DR   DrugBank; DB07202; 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE.
DR   DrugBank; DB12147; Erdafitinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB06080; Linifanib.
DR   DrugBank; DB12978; Pexidartinib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugCentral; P07333; -.
DR   GuidetoPHARMACOLOGY; 1806; -.
DR   TCDB; 8.A.23.1.41; the basigin (basigin) family.
DR   GlyConnect; 1955; 14 N-Linked glycans (3 sites).
DR   GlyGen; P07333; 12 sites, 14 N-linked glycans (3 sites).
DR   iPTMnet; P07333; -.
DR   PhosphoSitePlus; P07333; -.
DR   BioMuta; CSF1R; -.
DR   DMDM; 547770; -.
DR   EPD; P07333; -.
DR   jPOST; P07333; -.
DR   MassIVE; P07333; -.
DR   PaxDb; P07333; -.
DR   PeptideAtlas; P07333; -.
DR   PRIDE; P07333; -.
DR   ProteomicsDB; 51993; -. [P07333-1]
DR   ProteomicsDB; 5930; -.
DR   ABCD; P07333; 61 sequenced antibodies.
DR   Antibodypedia; 1201; 1896 antibodies from 44 providers.
DR   DNASU; 1436; -.
DR   Ensembl; ENST00000286301.7; ENSP00000286301.3; ENSG00000182578.14. [P07333-1]
DR   Ensembl; ENST00000543093.1; ENSP00000445282.1; ENSG00000182578.14. [P07333-2]
DR   Ensembl; ENST00000675795.1; ENSP00000501699.1; ENSG00000182578.14. [P07333-1]
DR   GeneID; 1436; -.
DR   KEGG; hsa:1436; -.
DR   MANE-Select; ENST00000675795.1; ENSP00000501699.1; NM_001288705.3; NP_001275634.1.
DR   UCSC; uc003lrm.3; human. [P07333-1]
DR   CTD; 1436; -.
DR   DisGeNET; 1436; -.
DR   GeneCards; CSF1R; -.
DR   GeneReviews; CSF1R; -.
DR   HGNC; HGNC:2433; CSF1R.
DR   HPA; ENSG00000182578; Tissue enhanced (lymphoid tissue, placenta).
DR   MalaCards; CSF1R; -.
DR   MIM; 164770; gene.
DR   MIM; 221820; phenotype.
DR   MIM; 618476; phenotype.
DR   neXtProt; NX_P07333; -.
DR   OpenTargets; ENSG00000182578; -.
DR   Orphanet; 556985; Early-onset calcifying leukoencephalopathy-skeletal dysplasia.
DR   Orphanet; 313808; Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia.
DR   PharmGKB; PA26936; -.
DR   VEuPathDB; HostDB:ENSG00000182578; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000155506; -.
DR   HOGENOM; CLU_000288_49_0_1; -.
DR   InParanoid; P07333; -.
DR   OMA; EQLACCE; -.
DR   OrthoDB; 236292at2759; -.
DR   PhylomeDB; P07333; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P07333; -.
DR   Reactome; R-HSA-449836; Other interleukin signaling.
DR   Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX.
DR   SignaLink; P07333; -.
DR   SIGNOR; P07333; -.
DR   BioGRID-ORCS; 1436; 11 hits in 1105 CRISPR screens.
DR   ChiTaRS; CSF1R; human.
DR   EvolutionaryTrace; P07333; -.
DR   GeneWiki; Colony_stimulating_factor_1_receptor; -.
DR   GenomeRNAi; 1436; -.
DR   Pharos; P07333; Tclin.
DR   PRO; PR:P07333; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P07333; protein.
DR   Bgee; ENSG00000182578; Expressed in granulocyte and 164 other tissues.
DR   ExpressionAtlas; P07333; baseline and differential.
DR   Genevisible; P07333; HS.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:1990682; C:CSF1-CSF1R complex; ISS:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019955; F:cytokine binding; IDA:UniProtKB.
DR   GO; GO:0005011; F:macrophage colony-stimulating factor receptor activity; IMP:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:BHF-UCL.
DR   GO; GO:0019903; F:protein phosphatase binding; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ARUK-UCL.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0008283; P:cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0045217; P:cell-cell junction maintenance; IMP:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; ISS:UniProtKB.
DR   GO; GO:0036006; P:cellular response to macrophage colony-stimulating factor stimulus; IMP:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0021879; P:forebrain neuron differentiation; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IBA:GO_Central.
DR   GO; GO:0030097; P:hemopoiesis; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0038145; P:macrophage colony-stimulating factor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0030225; P:macrophage differentiation; TAS:UniProtKB.
DR   GO; GO:0060603; P:mammary gland duct morphogenesis; TAS:UniProtKB.
DR   GO; GO:0061518; P:microglial cell proliferation; IEA:Ensembl.
DR   GO; GO:0030224; P:monocyte differentiation; TAS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0021772; P:olfactory bulb development; IEA:Ensembl.
DR   GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; ISS:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; ISS:UniProtKB.
DR   GO; GO:0044794; P:positive regulation by host of viral process; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:2000147; P:positive regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IGI:ARUK-UCL.
DR   GO; GO:0120041; P:positive regulation of macrophage proliferation; IGI:ARUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0045124; P:regulation of bone resorption; ISS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0002931; P:response to ischemia; ISS:ARUK-UCL.
DR   GO; GO:0031529; P:ruffle organization; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR030658; CSF-1_receptor.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PIRSF; PIRSF500947; CSF-1_receptor; 1.
DR   SMART; SM00409; IG; 5.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 5.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Disease variant; Disulfide bond; Glycoprotein; Immunity;
KW   Immunoglobulin domain; Inflammatory response; Innate immunity; Kinase;
KW   Membrane; Neurodegeneration; Nucleotide-binding; Phosphoprotein;
KW   Proto-oncogene; Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000255"
FT   CHAIN           20..972
FT                   /note="Macrophage colony-stimulating factor 1 receptor"
FT                   /id="PRO_0000016765"
FT   TOPO_DOM        20..517
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        518..538
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        539..972
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          21..104
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          107..197
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          203..290
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          299..399
FT                   /note="Ig-like C2-type 4"
FT   DOMAIN          402..502
FT                   /note="Ig-like C2-type 5"
FT   DOMAIN          582..910
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          542..574
FT                   /note="Regulatory juxtamembrane domain"
FT   REGION          796..818
FT                   /note="Activation loop"
FT   REGION          918..950
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        926..942
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        778
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         588..596
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         616
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         546
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:20489731"
FT   MOD_RES         561
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P09581"
FT   MOD_RES         699
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:20489731,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         708
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:20489731"
FT   MOD_RES         713
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         723
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:20489731"
FT   MOD_RES         809
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:20489731"
FT   MOD_RES         923
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P09581"
FT   MOD_RES         969
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P09581"
FT   CARBOHYD        45
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        73
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        153
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        240
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        275
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        302
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        335
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        353
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        412
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        428
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        480
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        42..84
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        127..177
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        224..278
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        419..485
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         297..306
FT                   /note="ESAYLNLSSE -> GTPSPSLCPA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_047757"
FT   VAR_SEQ         307..972
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_047758"
FT   VARIANT         32
FT                   /note="V -> G (in dbSNP:rs56048668)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042038"
FT   VARIANT         132
FT                   /note="P -> L (in BANDDOS; impairs phosphorylation of JNK
FT                   kinases upon stimulation with CSF1; dbSNP:rs1351319114)"
FT                   /evidence="ECO:0000269|PubMed:30982609"
FT                   /id="VAR_083140"
FT   VARIANT         245
FT                   /note="A -> S (in dbSNP:rs41338945)"
FT                   /id="VAR_061290"
FT   VARIANT         279
FT                   /note="V -> M (in dbSNP:rs3829986)"
FT                   /id="VAR_049718"
FT   VARIANT         362
FT                   /note="H -> R (in dbSNP:rs10079250)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042039"
FT   VARIANT         413
FT                   /note="G -> S (in dbSNP:rs34951517)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042040"
FT   VARIANT         481..972
FT                   /note="Missing (in BANDDOS; dbSNP:rs917027829)"
FT                   /evidence="ECO:0000269|PubMed:30982609"
FT                   /id="VAR_083141"
FT   VARIANT         536
FT                   /note="L -> V (in dbSNP:rs55942044)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042041"
FT   VARIANT         585..619
FT                   /note="GKTLGAGAFGKVVEATAFGLGKEDAVLKVAVKMLK -> A (in HDLS1)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067396"
FT   VARIANT         589
FT                   /note="G -> E (in HDLS1; dbSNP:rs281860268)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067397"
FT   VARIANT         627
FT                   /note="Missing (in BANDDOS; impairs phosphorylation of JNK
FT                   kinases upon stimulation with CSF1; dbSNP:rs1554101963)"
FT                   /evidence="ECO:0000269|PubMed:30982609"
FT                   /id="VAR_083142"
FT   VARIANT         633
FT                   /note="E -> K (in HDLS1; impairs autophosphorylation upon
FT                   stimulation with CSF1; dbSNP:rs281860269)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067398"
FT   VARIANT         643
FT                   /note="H -> Q (in BANDDOS; dbSNP:rs184499252)"
FT                   /evidence="ECO:0000269|PubMed:30982608"
FT                   /id="VAR_083143"
FT   VARIANT         653
FT                   /note="C -> R (in HDLS1; dbSNP:rs690016559)"
FT                   /evidence="ECO:0000269|PubMed:24532199"
FT                   /id="VAR_072081"
FT   VARIANT         693
FT                   /note="P -> H (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042042"
FT   VARIANT         710
FT                   /note="R -> H (in dbSNP:rs201569135)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067399"
FT   VARIANT         747
FT                   /note="G -> R (in dbSNP:rs41355444)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067400"
FT   VARIANT         765
FT                   /note="G -> D (in HDLS1; impairs autophosphorylation upon
FT                   stimulation with CSF1; dbSNP:rs690016566)"
FT                   /evidence="ECO:0000269|PubMed:24336230"
FT                   /id="VAR_083144"
FT   VARIANT         766
FT                   /note="M -> T (in HDLS1; impairs autophosphorylation upon
FT                   stimulation with CSF1; dbSNP:rs281860270)"
FT                   /evidence="ECO:0000269|PubMed:22197934,
FT                   ECO:0000269|PubMed:23408870"
FT                   /id="VAR_067401"
FT   VARIANT         770
FT                   /note="A -> P (in HDLS1; dbSNP:rs281860271)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067402"
FT   VARIANT         774..814
FT                   /note="Missing (in HDLS1)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067403"
FT   VARIANT         775
FT                   /note="I -> N (in HDLS1; impairs autophosphorylation upon
FT                   stimulation with CSF1; dbSNP:rs281860273)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067404"
FT   VARIANT         781
FT                   /note="A -> E (in HDLS1; impairs autophosphorylation upon
FT                   stimulation with CSF1; dbSNP:rs587777247)"
FT                   /evidence="ECO:0000269|PubMed:24336230"
FT                   /id="VAR_083145"
FT   VARIANT         782
FT                   /note="R -> H (in HDLS1; impairs autophosphorylation upon
FT                   stimulation with CSF1; dbSNP:rs281860281)"
FT                   /evidence="ECO:0000269|PubMed:23408870"
FT                   /id="VAR_083146"
FT   VARIANT         794
FT                   /note="I -> T (in HDLS1; impairs autophosphorylation upon
FT                   stimulation with CSF1; dbSNP:rs281860274)"
FT                   /evidence="ECO:0000269|PubMed:22197934,
FT                   ECO:0000269|PubMed:24336230"
FT                   /id="VAR_067405"
FT   VARIANT         824
FT                   /note="P -> S (in HDLS1; impairs autophosphorylation upon
FT                   stimulation with CSF1)"
FT                   /evidence="ECO:0000269|PubMed:24336230"
FT                   /id="VAR_083147"
FT   VARIANT         837
FT                   /note="D -> Y (in HDLS1; dbSNP:rs387906662)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067406"
FT   VARIANT         843
FT                   /note="I -> F (in HDLS1; dbSNP:rs690016558)"
FT                   /evidence="ECO:0000269|PubMed:24532199"
FT                   /id="VAR_072082"
FT   VARIANT         849
FT                   /note="F -> S (in HDLS1; dbSNP:rs281860277)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067407"
FT   VARIANT         849
FT                   /note="Missing (in HDLS1)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067408"
FT   VARIANT         868
FT                   /note="L -> P (in HDLS1; dbSNP:rs281860278)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067409"
FT   VARIANT         875
FT                   /note="M -> T (in HDLS1; impairs autophosphorylation upon
FT                   stimulation with CSF1; dbSNP:rs281860279)"
FT                   /evidence="ECO:0000269|PubMed:22197934,
FT                   ECO:0000269|PubMed:23408870"
FT                   /id="VAR_067410"
FT   VARIANT         878
FT                   /note="P -> T (in HDLS1; dbSNP:rs281860280)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067411"
FT   VARIANT         906
FT                   /note="I -> T (in HDLS1; dbSNP:rs690016560)"
FT                   /evidence="ECO:0000269|PubMed:24532199"
FT                   /id="VAR_072083"
FT   VARIANT         920
FT                   /note="E -> D (in dbSNP:rs34030164)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:22197934"
FT                   /id="VAR_042043"
FT   VARIANT         921
FT                   /note="R -> Q (in dbSNP:rs56059682)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042044"
FT   VARIANT         969
FT                   /note="Y -> C (in dbSNP:rs1801271)"
FT                   /id="VAR_011953"
FT   MUTAGEN         301
FT                   /note="L->S: Constitutive kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15117969"
FT   MUTAGEN         708
FT                   /note="Y->F: Impairs degradation of activated CSF1R."
FT                   /evidence="ECO:0000269|PubMed:10340379"
FT   MUTAGEN         802
FT                   /note="D->V: Constitutive kinase activity. Loss of
FT                   inhibition by imatinib."
FT                   /evidence="ECO:0000269|PubMed:10340379,
FT                   ECO:0000269|PubMed:16170366"
FT   MUTAGEN         809
FT                   /note="Y->F: Reduced kinase activity. Reduced interaction
FT                   with SRC, FYN and YES1."
FT                   /evidence="ECO:0000269|PubMed:7681396"
FT   MUTAGEN         969
FT                   /note="Y->F: Abolishes down-regulation of activated CSF1R."
FT                   /evidence="ECO:0000269|PubMed:15117969"
FT   CONFLICT        54
FT                   /note="P -> A (in Ref. 2; CAA27300)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="P -> H (in Ref. 7; AAH47521)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        354
FT                   /note="A -> V (in Ref. 7; AAH47521)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        629
FT                   /note="A -> S (in Ref. 7; AAH47521)"
FT                   /evidence="ECO:0000305"
FT   STRAND          22..25
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          27..32
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          38..43
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          49..51
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   TURN            55..57
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          58..62
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          64..73
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   HELIX           76..78
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          80..85
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          95..101
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          108..111
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          113..118
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          123..125
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          127..130
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   HELIX           132..137
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          139..142
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   HELIX           143..145
FT                   /evidence="ECO:0007829|PDB:4WRL"
FT   STRAND          154..157
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   TURN            158..160
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          161..166
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   HELIX           169..171
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          173..181
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          184..187
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          191..196
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          204..208
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          210..215
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          216..218
FT                   /evidence="ECO:0007829|PDB:4DKD"
FT   STRAND          220..231
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          234..239
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          248..252
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          257..267
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   TURN            270..272
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          274..282
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          285..298
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          300..304
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          309..314
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          319..329
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          332..338
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          340..342
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          351..354
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          361..368
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   HELIX           373..375
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          377..385
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          388..411
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          414..425
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          428..437
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   TURN            443..445
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          446..454
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          456..459
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          466..473
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          479..488
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          493..498
FT                   /evidence="ECO:0007829|PDB:4LIQ"
FT   STRAND          551..553
FT                   /evidence="ECO:0007829|PDB:6IG8"
FT   STRAND          556..560
FT                   /evidence="ECO:0007829|PDB:3BEA"
FT   HELIX           566..568
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           573..575
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           579..581
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   STRAND          582..590
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   STRAND          592..604
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   TURN            605..608
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   STRAND          609..618
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           624..640
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   STRAND          649..653
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   STRAND          655..658
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   STRAND          660..664
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           671..680
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   TURN            684..686
FT                   /evidence="ECO:0007829|PDB:6IG8"
FT   TURN            742..744
FT                   /evidence="ECO:0007829|PDB:2OGV"
FT   HELIX           752..771
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           781..783
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   STRAND          784..787
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           788..790
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   STRAND          791..794
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   TURN            798..800
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           803..805
FT                   /evidence="ECO:0007829|PDB:2I1M"
FT   TURN            806..808
FT                   /evidence="ECO:0007829|PDB:3LCO"
FT   STRAND          809..812
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   STRAND          815..817
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           819..821
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           824..829
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           834..849
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           863..870
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           883..892
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           897..899
FT                   /evidence="ECO:0007829|PDB:6T2W"
FT   HELIX           903..915
FT                   /evidence="ECO:0007829|PDB:6T2W"
SQ   SEQUENCE   972 AA;  107984 MW;  A8D99BE237573FE8 CRC64;
     MGPGVLLLLL VATAWHGQGI PVIEPSVPEL VVKPGATVTL RCVGNGSVEW DGPPSPHWTL
     YSDGSSSILS TNNATFQNTG TYRCTEPGDP LGGSAAIHLY VKDPARPWNV LAQEVVVFED
     QDALLPCLLT DPVLEAGVSL VRVRGRPLMR HTNYSFSPWH GFTIHRAKFI QSQDYQCSAL
     MGGRKVMSIS IRLKVQKVIP GPPALTLVPA ELVRIRGEAA QIVCSASSVD VNFDVFLQHN
     NTKLAIPQQS DFHNNRYQKV LTLNLDQVDF QHAGNYSCVA SNVQGKHSTS MFFRVVESAY
     LNLSSEQNLI QEVTVGEGLN LKVMVEAYPG LQGFNWTYLG PFSDHQPEPK LANATTKDTY
     RHTFTLSLPR LKPSEAGRYS FLARNPGGWR ALTFELTLRY PPEVSVIWTF INGSGTLLCA
     ASGYPQPNVT WLQCSGHTDR CDEAQVLQVW DDPYPEVLSQ EPFHKVTVQS LLTVETLEHN
     QTYECRAHNS VGSGSWAFIP ISAGAHTHPP DEFLFTPVVV ACMSIMALLL LLLLLLLYKY
     KQKPKYQVRW KIIESYEGNS YTFIDPTQLP YNEKWEFPRN NLQFGKTLGA GAFGKVVEAT
     AFGLGKEDAV LKVAVKMLKS TAHADEKEAL MSELKIMSHL GQHENIVNLL GACTHGGPVL
     VITEYCCYGD LLNFLRRKAE AMLGPSLSPG QDPEGGVDYK NIHLEKKYVR RDSGFSSQGV
     DTYVEMRPVS TSSNDSFSEQ DLDKEDGRPL ELRDLLHFSS QVAQGMAFLA SKNCIHRDVA
     ARNVLLTNGH VAKIGDFGLA RDIMNDSNYI VKGNARLPVK WMAPESIFDC VYTVQSDVWS
     YGILLWEIFS LGLNPYPGIL VNSKFYKLVK DGYQMAQPAF APKNIYSIMQ ACWALEPTHR
     PTFQQICSFL QEQAQEDRRE RDYTNLPSSS RSGGSGSSSS ELEEESSSEH LTCCEQGDIA
     QPLLQPNNYQ FC
//
